Home /Research /81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
OTHER

81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results

Chuhl Joo Lyu, Wentao Fang, Weiqi Jiao, Haitao Ma, J. Wang, S. Xu, Nan Wu, R. Wang, Yongbo Yang

Year
2022
Citations
10

Keywords

MedicineOsimertinibNeoadjuvant therapyClinical endpointAdenocarcinomaAdverse effectInternal medicineLung cancerPopulationSurgery

Related papers

Browse all OTHER papers